Who Shouldn't Take Fosfomycin
Fosfomycin is contraindicated only in patients with documented hypersensitivity to the drug 1. Beyond this absolute contraindication, several patient populations require careful consideration or alternative therapy.
Absolute Contraindication
- Known hypersensitivity to fosfomycin or its excipients 1
Populations Requiring Caution or Alternative Therapy
Severe Renal Impairment
Patients with severe renal dysfunction (creatinine clearance <10 mL/min or anuric patients) should generally avoid fosfomycin or receive it only with extreme caution. The drug's half-life increases dramatically in renal failure—from 5.7 hours in normal function to 40-50 hours in anuric patients 1. In patients with creatinine clearance ranging from 54 to 7 mL/min, the elimination half-life extends from 11 to 50 hours, with urinary recovery dropping from 32% to 11% 1.
However, recent evidence suggests this may be overly restrictive for moderate renal impairment. A 2017 study in solid organ transplant recipients demonstrated that fosfomycin maintained 80% treatment success even with creatinine clearance <40 mL/min, with no significant difference compared to those with normal renal function 2. For moderate renal impairment (CrCl 10-50 mL/min), dose adjustment is necessary but the drug remains usable 3.
Pediatric Patients
Children under 12 years of age should not receive oral fosfomycin tromethamine, as safety and effectiveness have not been established in adequate controlled studies 1. This applies specifically to the oral formulation.
For intravenous fosfomycin, the situation differs:
- Infants under 1 year require careful dosing based on postmenstrual age, with the lowest recommended dose (100 mg/kg/day) reserved only for pre-term neonates with postmenstrual age below 40 weeks 4
- Recent 2024 data support IV fosfomycin safety in children for complicated infections, showing good efficacy with minimal adverse effects 5
Pregnancy and Lactation
Fosfomycin can be used in pregnancy but requires careful consideration. The drug crosses the placental barrier 1, though animal studies show no teratogenic effects at high doses. The 2019 IDSA guideline notes that single-dose fosfomycin is effective for clearing bacteriuria in pregnancy, but outcomes like pyelonephritis and preterm labor are not yet well-studied for this regimen 6. When used in pregnancy, a 4-7 day course is preferred over single-dose therapy based on better outcomes with nitrofurantoin and beta-lactams 6.
For lactating women, the decision to use fosfomycin requires weighing maternal benefit against potential infant risk, as it is unknown whether the drug is excreted in human milk 1.
Special Considerations
Drug Interactions
- Avoid co-administration with metoclopramide or other drugs that increase gastrointestinal motility, as these significantly lower fosfomycin serum concentrations and urinary excretion 1
- Cimetidine does not affect fosfomycin pharmacokinetics and can be used safely 1
Hepatotoxicity Risk
While rare, severe acute hepatitis has been reported with fosfomycin 7. Monitor for signs of liver injury in all patients, particularly those with pre-existing hepatic conditions, though this is not an absolute contraindication.
Patients on Hemodialysis
Anuric patients on hemodialysis face a 40-hour elimination half-life 1, making standard dosing inappropriate. These patients require either dose reduction, extended intervals, or alternative therapy.
Clinical Pitfalls to Avoid
Don't automatically exclude patients with moderate renal impairment (CrCl 10-50 mL/min)—adjust dosing rather than avoiding the drug entirely 3, 2
Don't use oral fosfomycin in children under 12 years—the IV formulation has better pediatric data 1, 4
Don't combine with metoclopramide—this significantly reduces drug efficacy 1
Don't assume single-dose therapy is adequate in pregnancy—use 4-7 day courses 6